미국의 뇌종양 시장 규모, 점유율, 동향 분석 보고서 : 종양 유형별, 치료 유형별, 부문 예측(2025-2034년)

U.S. Brain Tumor Market Growth & Trends:

The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.

Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.

The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.

U.S. Brain Tumor Market Report Highlights:

• Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors
• Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy
• Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research in the U.S.
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Tumor Type outlook
  • 2.2.2. Treatment Type outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of primary and secondary brain tumors
    • 3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
    • 3.2.1.3. Increasing awareness and early diagnosis of brain tumor
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High treatment costs
    • 3.2.2.2. Side effects and complications associated with brain tumor treatrment
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Increasing number of clinical trials
    • 3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Product recalls
    • 3.2.4.2. Stringent regulations
• 3.3. U.S. Brain tumor Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Tumor Type Market Share, 2024 & 2034
• 4.3. Segment Dashboard
• 4.4. U.S. Brain Tumor Market by Tumor Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
  • 4.5.1. Malignant
    • 4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.2. Glioblastomas
      • 4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.3. Medulloblastomas
      • 4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.4. Astrocytomas
      • 4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.5. Ependymomas
      • 4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1.6. Others
      • 4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
  • 4.5.2. Non-Malignant
    • 4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.2. Meningiomas
      • 4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.3. Pituitary Adenomas
      • 4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.4. Craniopharyngiomas
      • 4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.5. Hemangioblastomas
      • 4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2.6. Others
      • 4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)

Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Treatment Type Market Share, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. U.S. Brain Tumor Market by Treatment Type Outlook
• 5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
  • 5.5.1. Surgery
    • 5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 5.5.1.2. Neurosurgical Instruments
      • 5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.3. Robotic Surgery Systems
      • 5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.4. Interventional Device-Based Procedures
      • 5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.5. Endoscopes
      • 5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.6. Intraoperative Imaging Systems
      • 5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.1.7. Others
      • 5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.2. Radiation Therapy
    • 5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
      • 5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.2. Linear Accelerators (LINAC)
        • 5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.3. Gamma Knife Systems
        • 5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2.4. Proton radiosurgery
        • 5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2.3. Internal radiation/Brachytherapy devices
      • 5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.3. Interventional Device-Based Procedures
    • 5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3.2. Embolization Devices
      • 5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2.2. Liquid Embolic Agents
        • 5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2.3. Microspheres
        • 5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3.3. Tumor Ablation Devices
      • 5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.4. Chemotherapy
    • 5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.5. Targeted Therapy
    • 5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.6. Tumor Treating Fields (TTF)
    • 5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.7. Laser Interstitial Thermal Therapy (LITT)
    • 5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.8. Surgically Targeted Radiation Therapy
    • 5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.9. Catheter-Based Ultrasound Thermal Ablation
    • 5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.10. Focused Ultrasound (FUS)
    • 5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.5.11. Low-Intensity Focused Ultrasound (LIFU)
    • 5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
• 5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
  • 5.6.1. Surgery
    • 5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 5.6.1.2. Neurosurgical Instruments
      • 5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.2. Blade, Knife, Cutter & Scissors
        • 5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.3. Dissector
        • 5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.4. Drill & Perforator
        • 5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.2.5. Others
        • 5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.3. Robotic Surgery Systems
      • 5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.4. Endoscopes
      • 5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.5. Intraoperative Imaging Systems
      • 5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.1.6. Others
      • 5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6.2. Radiation Therapy
    • 5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
      • 5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.2. Linear Accelerators (LINAC)
        • 5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.3. Gamma Knife Systems
        • 5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2.4. Proton radiosurgery
        • 5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2.3. Internal radiation/Brachytherapy Devices
      • 5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6.3. Other Monitoring Devices
    • 5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
  • 6.2.1. Innovators
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key company market share analysis, 2024
  • 6.3.4. GT Medical Technologies, Inc.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Novocure
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. ZAP Surgical Systems, Inc.
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Aesculap, Inc. - a B. Braun company
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Accuray Incorporated
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Carthera
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Alpheus Medical Inc.
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Alpha Tau Medical Ltd
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Elekta
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives
  • 6.3.13. IMRIS Inc.
    • 6.3.13.1. Company overview
    • 6.3.13.2. Financial performance
    • 6.3.13.3. Product benchmarking
    • 6.3.13.4. Strategic initiatives
  • 6.3.14. Medtronic
    • 6.3.14.1. Company overview
    • 6.3.14.2. Financial performance
    • 6.3.14.3. Product benchmarking
    • 6.3.14.4. Strategic initiatives
  • 6.3.15. Monteris
    • 6.3.15.1. Company overview
    • 6.3.15.2. Financial performance
    • 6.3.15.3. Product benchmarking
    • 6.3.15.4. Strategic initiatives
  • 6.3.16. Openwater
    • 6.3.16.1. Company overview
    • 6.3.16.2. Financial performance
    • 6.3.16.3. Product benchmarking
    • 6.3.16.4. Strategic initiatives
  • 6.3.17. Acoustic MedSystems, Inc.
    • 6.3.17.1. Company overview
    • 6.3.17.2. Financial performance
    • 6.3.17.3. Product benchmarking
    • 6.3.17.4. Strategic initiatives
  • 6.3.18. NaviFUS Corp
    • 6.3.18.1. Company overview
    • 6.3.18.2. Financial performance
    • 6.3.18.3. Product benchmarking
    • 6.3.18.4. Strategic initiatives
  • 6.3.19. Insightec
    • 6.3.19.1. Company overview
    • 6.3.19.2. Financial performance
    • 6.3.19.3. Product benchmarking
    • 6.3.19.4. Strategic initiatives
  • 6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
    • 6.3.20.1. Company overview
    • 6.3.20.2. Financial performance
    • 6.3.20.3. Product benchmarking
    • 6.3.20.4. Strategic initiatives
  • 6.3.21. RefleXion
    • 6.3.21.1. Company overview
    • 6.3.21.2. Financial performance
    • 6.3.21.3. Product benchmarking
    • 6.3.21.4. Strategic initiatives
  • 6.3.22. MagnetTx Oncology Solutions Ltd.
    • 6.3.22.1. Company overview
    • 6.3.22.2. Financial performance
    • 6.3.22.3. Product benchmarking
    • 6.3.22.4. Strategic initiatives
  • 6.3.23. NICO Corporation (Stryker)
    • 6.3.23.1. Company overview
    • 6.3.23.2. Financial performance
    • 6.3.23.3. Product benchmarking
    • 6.3.23.4. Strategic initiatives
  • 6.3.24. Terumo Interventional Systems
    • 6.3.24.1. Company overview
    • 6.3.24.2. Financial performance
    • 6.3.24.3. Product benchmarking
    • 6.3.24.4. Strategic initiatives
  • 6.3.25. Boston Scientific Corporation
    • 6.3.25.1. Company overview
    • 6.3.25.2. Financial performance
    • 6.3.25.3. Product benchmarking
    • 6.3.25.4. Strategic initiatives
  • 6.3.26. Koninklijke Philips N.V.
    • 6.3.26.1. Company overview
    • 6.3.26.2. Financial performance
    • 6.3.26.3. Product benchmarking
    • 6.3.26.4. Strategic initiatives
  • 6.3.27. IBA Worldwide
    • 6.3.27.1. Company overview
    • 6.3.27.2. Financial performance
    • 6.3.27.3. Product benchmarking
    • 6.3.27.4. Strategic initiatives